source
- Avalyn Pharma CEO shares personal moment as company prepares for Nasdaq IPOAvalyn Pharma and Generate Biomedicines executives talked about the long hours and challenges of preparing their companies for an initial public offering. Avalyn CEO Lyn Baranowski highlighted a m…
- Epilepsy drug from Ovid and Takeda receives fresh start under Perceptive-backed ventureAfter about 26 months since two Phase 3 trials failed, the epilepsy treatment candidate originally developed by Ovid Therapeutics and Takeda has been removed from their pipelines. Investment firm…